Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70864 | 0.91 | PTPN1 (0.47) | TSHRCYP2C19CYP1A2CYP2C9SPHK1 | |
| SCHEMBL9304492 | 0.85 | TSHR (0.54) | TSHRCYP2C19CYP1A2CYP2C9SPHK1 | |
| SCHEMBL27952824 | 0.85 | ALDH1A1 (0.47) | TSHRSPHK1MEN1KMT2ANPC1 | |
| SCHEMBL2151745 | 0.84 | SMN1; SMN2 (0.51) | TSHRCYP2C19CYP1A2CYP2C9SPHK1 | |
| SCHEMBL18542894 | 0.83 | CA12 (0.41) | SPHK1EPHX1EPHX2 | |
| SCHEMBL105727 | 0.83 | EGFR (0.52) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL14817483 | 0.82 | NAPRT (0.53) | TSHRCYP2C19CYP1A2CYP2C9SPHK1 | |
| SCHEMBL106428 | 0.82 | SPHK1 (0.50) | TSHRCYP2C19CYP1A2CYP2C9SPHK1 | |
| SCHEMBL10202156 | 0.81 | TSHR (0.48) | TSHRCYP2C19CYP1A2CYP2C9SPHK1 | |
| SCHEMBL24444629 | 0.79 | LMNA (0.58) | SPHK1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021163192-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2017029362-A1 | ASYMMETRIC BISAMIDATION OF MALONIC ESTER DERIVATIVES | SANDOZ AG (CH) | 2017-02-23 | — | — | WO | disclosed |
| US-20150218130-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| CN-103068384-B | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activity | DECIPHERA PHARMACEUTICALS LLC | 2015-03-11 | — | — | CN | disclosed |
| US-20140194405-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2563362-B1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8637672-B2 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2563362-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | Deciphera Pharmaceuticals, LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHAMACEUTICALS, LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011137342-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | MYC, AURKA, AURKC | TSHR 4277/4885CYP2C19 4783/4885CYP1A2 4628/4885 |
| US-20140194405-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 4512/4885CYP2C19 4205/4885CYP1A2 3596/4885 |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 4512/4885CYP2C19 4205/4885CYP1A2 3596/4885 |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 4512/4885CYP2C19 4205/4885CYP1A2 3596/4885 |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 4512/4885CYP2C19 4205/4885CYP1A2 3596/4885 |
| US-20150218130-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 4512/4885CYP2C19 4205/4885CYP1A2 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.